As of Jun 29
| -0.91 / -7.32%|
The 5 analysts offering 12-month price forecasts for Stemline Therapeutics Inc have a median target of 38.00, with a high estimate of 50.00 and a low estimate of 30.00. The median estimate represents a +229.86% increase from the last price of 11.52.
The current consensus among 5 polled investment analysts is to Buy stock in Stemline Therapeutics Inc. This rating has held steady since June, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.